133 related articles for article (PubMed ID: 10525079)
1. Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis.
Lark MW; Stroup GB; Hwang SM; James IE; Rieman DJ; Drake FH; Bradbeer JN; Mathur A; Erhard KF; Newlander KA; Ross ST; Salyers KL; Smith BR; Miller WH; Huffman WF; Gowen M
J Pharmacol Exp Ther; 1999 Nov; 291(2):612-7. PubMed ID: 10525079
[TBL] [Abstract][Full Text] [Related]
2. Antagonism of the osteoclast vitronectin receptor with an orally active nonpeptide inhibitor prevents cancellous bone loss in the ovariectomized rat.
Lark MW; Stroup GB; Dodds RA; Kapadia R; Hoffman SJ; Hwang SM; James IE; Lechowska B; Liang X; Rieman DJ; Salyers KL; Ward K; Smith BR; Miller WH; Huffman WF; Gowen M
J Bone Miner Res; 2001 Feb; 16(2):319-27. PubMed ID: 11204432
[TBL] [Abstract][Full Text] [Related]
3. Contortrostatin, a homodimeric snake venom disintegrin, is a potent inhibitor of osteoclast attachment.
Mercer B; Markland F; Minkin C
J Bone Miner Res; 1998 Mar; 13(3):409-14. PubMed ID: 9525341
[TBL] [Abstract][Full Text] [Related]
4. Integrin function in osteoclasts.
Rodan SB; Rodan GA
J Endocrinol; 1997 Sep; 154 Suppl():S47-56. PubMed ID: 9379137
[TBL] [Abstract][Full Text] [Related]
5. A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo.
Engleman VW; Nickols GA; Ross FP; Horton MA; Griggs DW; Settle SL; Ruminski PG; Teitelbaum SL
J Clin Invest; 1997 May; 99(9):2284-92. PubMed ID: 9151803
[TBL] [Abstract][Full Text] [Related]
6. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys.
Kumar S; Dare L; Vasko-Moser JA; James IE; Blake SM; Rickard DJ; Hwang SM; Tomaszek T; Yamashita DS; Marquis RW; Oh H; Jeong JU; Veber DF; Gowen M; Lark MW; Stroup G
Bone; 2007 Jan; 40(1):122-31. PubMed ID: 16962401
[TBL] [Abstract][Full Text] [Related]
7. A peptidomimetic antagonist of the integrin alpha(v)beta3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy.
Carron CP; Meyer DM; Pegg JA; Engleman VW; Nickols MA; Settle SL; Westlin WF; Ruminski PG; Nickols GA
Cancer Res; 1998 May; 58(9):1930-5. PubMed ID: 9581835
[TBL] [Abstract][Full Text] [Related]
8. Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats.
Santulli RJ; Kinney WA; Ghosh S; Decorte BL; Liu L; Tuman RW; Zhou Z; Huebert N; Bursell SE; Clermont AC; Grant MB; Shaw LC; Mousa SA; Galemmo RA; Johnson DL; Maryanoff BE; Damiano BP
J Pharmacol Exp Ther; 2008 Mar; 324(3):894-901. PubMed ID: 18083913
[TBL] [Abstract][Full Text] [Related]
9. SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity.
Wilkinson-Berka JL; Jones D; Taylor G; Jaworski K; Kelly DJ; Ludbrook SB; Willette RN; Kumar S; Gilbert RE
Invest Ophthalmol Vis Sci; 2006 Apr; 47(4):1600-5. PubMed ID: 16565398
[TBL] [Abstract][Full Text] [Related]
10. The integrin ligand echistatin prevents bone loss in ovariectomized mice and rats.
Yamamoto M; Fisher JE; Gentile M; Seedor JG; Leu CT; Rodan SB; Rodan GA
Endocrinology; 1998 Mar; 139(3):1411-9. PubMed ID: 9492078
[TBL] [Abstract][Full Text] [Related]
11. Disease-modifying activity of SB 273005, an orally active, nonpeptide alphavbeta3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis.
Badger AM; Blake S; Kapadia R; Sarkar S; Levin J; Swift BA; Hoffman SJ; Stroup GB; Miller WH; Gowen M; Lark MW
Arthritis Rheum; 2001 Jan; 44(1):128-37. PubMed ID: 11212150
[TBL] [Abstract][Full Text] [Related]
12. Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate.
Stroup GB; Lark MW; Veber DF; Bhattacharyya A; Blake S; Dare LC; Erhard KF; Hoffman SJ; James IE; Marquis RW; Ru Y; Vasko-Moser JA; Smith BR; Tomaszek T; Gowen M
J Bone Miner Res; 2001 Oct; 16(10):1739-46. PubMed ID: 11585335
[TBL] [Abstract][Full Text] [Related]
13. Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo.
Votta BJ; Levy MA; Badger A; Bradbeer J; Dodds RA; James IE; Thompson S; Bossard MJ; Carr T; Connor JR; Tomaszek TA; Szewczuk L; Drake FH; Veber DF; Gowen M
J Bone Miner Res; 1997 Sep; 12(9):1396-406. PubMed ID: 9286755
[TBL] [Abstract][Full Text] [Related]
14. A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat.
Lark MW; Stroup GB; James IE; Dodds RA; Hwang SM; Blake SM; Lechowska BA; Hoffman SJ; Smith BR; Kapadia R; Liang X; Erhard K; Ru Y; Dong X; Marquis RW; Veber D; Gowen M
Bone; 2002 May; 30(5):746-53. PubMed ID: 11996914
[TBL] [Abstract][Full Text] [Related]
15. Peptidomimetic antagonists of alphavbeta3 inhibit bone resorption by inhibiting osteoclast bone resorptive activity, not osteoclast adhesion to bone.
Carron CP; Meyer DM; Engleman VW; Rico JG; Ruminski PG; Ornberg RL; Westlin WF; Nickols GA
J Endocrinol; 2000 Jun; 165(3):587-98. PubMed ID: 10828842
[TBL] [Abstract][Full Text] [Related]
16. Absence of platelet-activating factor receptor protects mice from osteoporosis following ovariectomy.
Hikiji H; Ishii S; Shindou H; Takato T; Shimizu T
J Clin Invest; 2004 Jul; 114(1):85-93. PubMed ID: 15232615
[TBL] [Abstract][Full Text] [Related]
17. An orally active cathepsin K inhibitor, furan-2-carboxylic acid, 1-{1-[4-fluoro-2-(2-oxo-pyrrolidin-1-yl)-phenyl]-3-oxo-piperidin-4-ylcarbamoyl}-cyclohexyl)-amide (OST-4077), inhibits osteoclast activity in vitro and bone loss in ovariectomized rats.
Kim MK; Kim HD; Park JH; Lim JI; Yang JS; Kwak WY; Sung SY; Kim HJ; Kim SH; Lee CH; Shim JY; Bae MH; Shin YA; Huh Y; Han TD; Chong W; Choi H; Ahn BN; Yang SO; Son MH
J Pharmacol Exp Ther; 2006 Aug; 318(2):555-62. PubMed ID: 16699068
[TBL] [Abstract][Full Text] [Related]
18. Novel potent and selective alphavbeta3/alphavbeta5 integrin dual antagonists with reduced binding affinity for human serum albumin.
Raboisson P; Manthey CL; Chaikin M; Lattanze J; Crysler C; Leonard K; Pan W; Tomczuk BE; Marugán JJ
Eur J Med Chem; 2006 Jul; 41(7):847-61. PubMed ID: 16697080
[TBL] [Abstract][Full Text] [Related]
19. The chloride channel inhibitor NS3736 [corrected] prevents bone resorption in ovariectomized rats without changing bone formation.
Schaller S; Henriksen K; Sveigaard C; Heegaard AM; Hélix N; Stahlhut M; Ovejero MC; Johansen JV; Solberg H; Andersen TL; Hougaard D; Berryman M; Shiødt CB; Sørensen BH; Lichtenberg J; Christophersen P; Foged NT; Delaissé JM; Engsig MT; Karsdal MA
J Bone Miner Res; 2004 Jul; 19(7):1144-53. PubMed ID: 15176998
[TBL] [Abstract][Full Text] [Related]
20. Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model.
Miller WH; Bondinell WE; Cousins RD; Erhard KF; Jakas DR; Keenan RM; Ku TW; Newlander KA; Ross ST; Haltiwanger RC; Bradbeer J; Drake FH; Gowen M; Hoffman SJ; Hwang SM; James IE; Lark MW; Lechowska B; Rieman DJ; Stroup GB; Vasko-Moser JA; Zembryki DL; Azzarano LM; Adams PC; Huffman WF
Bioorg Med Chem Lett; 1999 Jul; 9(13):1807-12. PubMed ID: 10406646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
